JP2004538259A5 - - Google Patents

Download PDF

Info

Publication number
JP2004538259A5
JP2004538259A5 JP2002576195A JP2002576195A JP2004538259A5 JP 2004538259 A5 JP2004538259 A5 JP 2004538259A5 JP 2002576195 A JP2002576195 A JP 2002576195A JP 2002576195 A JP2002576195 A JP 2002576195A JP 2004538259 A5 JP2004538259 A5 JP 2004538259A5
Authority
JP
Japan
Prior art keywords
formula
solvate
physiologically functional
salt
functional derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002576195A
Other languages
English (en)
Japanese (ja)
Other versions
JP4143413B2 (ja
JP2004538259A (ja
Filing date
Publication date
Priority claimed from GB0107213A external-priority patent/GB0107213D0/en
Priority claimed from GB0126995A external-priority patent/GB0126995D0/en
Application filed filed Critical
Priority claimed from PCT/EP2002/003122 external-priority patent/WO2002076933A1/en
Publication of JP2004538259A publication Critical patent/JP2004538259A/ja
Publication of JP2004538259A5 publication Critical patent/JP2004538259A5/ja
Application granted granted Critical
Publication of JP4143413B2 publication Critical patent/JP4143413B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002576195A 2001-03-22 2002-03-20 β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体 Expired - Fee Related JP4143413B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0107213A GB0107213D0 (en) 2001-03-22 2001-03-22 Chemical compounds
GB0126995A GB0126995D0 (en) 2001-11-09 2001-11-09 Chemical compounds
PCT/EP2002/003122 WO2002076933A1 (en) 2001-03-22 2002-03-20 Formailide derivatives as beta2-adrenoreceptor agonists

Publications (3)

Publication Number Publication Date
JP2004538259A JP2004538259A (ja) 2004-12-24
JP2004538259A5 true JP2004538259A5 (enExample) 2005-12-22
JP4143413B2 JP4143413B2 (ja) 2008-09-03

Family

ID=26245880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002576195A Expired - Fee Related JP4143413B2 (ja) 2001-03-22 2002-03-20 β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体

Country Status (7)

Country Link
US (1) US7045658B2 (enExample)
EP (1) EP1370521B1 (enExample)
JP (1) JP4143413B2 (enExample)
AT (1) ATE381537T1 (enExample)
DE (1) DE60224172T2 (enExample)
ES (1) ES2296923T3 (enExample)
WO (1) WO2002076933A1 (enExample)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
CO5310534A1 (es) 2000-08-05 2003-08-29 Glaxo Group Ltd Nuevos derivados de androstano anti-inflamatorios
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
ES2314052T3 (es) 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.
EP1487417A4 (en) 2001-09-17 2010-03-17 Glaxo Group Ltd DRY POWDER DRUG FORMULATIONS
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
EP1471895B2 (en) * 2002-02-04 2012-03-14 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
SI1567139T1 (sl) * 2002-11-27 2008-12-31 Nycomed Gmbh Nova sinergistična kombinacija, ki obsega roflumilast in formoterol
PT1567140E (pt) * 2002-11-27 2008-09-24 Nycomed Gmbh Combinação sinérgica compreendendo roflumilaste e (r,r)-formoterol
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
EP1622875B1 (en) 2003-05-08 2009-12-02 Theravance, Inc. Crystalline forms of an arylaniline beta-2 adrenergic receptor agonist
TW200510277A (en) 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
RU2006146042A (ru) * 2004-06-03 2008-07-20 Тереванс Диаминные агонисты 2-адренергических рецепторов
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
EP1786762A2 (en) * 2004-09-10 2007-05-23 Theravance, Inc. Amidine substituted aryl aniline compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US7579335B2 (en) 2005-01-10 2009-08-25 Glaxo Group Limited Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
TWI389690B (zh) 2005-03-25 2013-03-21 Glaxo Group Ltd 新穎化合物（一）
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
CA2620281A1 (en) * 2005-08-26 2007-03-01 Astrazeneca Ab A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
CA2649509A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
WO2007121920A2 (en) 2006-04-21 2007-11-01 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
TW200817006A (en) 2006-06-23 2008-04-16 Smithkline Beecham Corp IL-8 receptor antagonist
US20090291976A1 (en) * 2006-06-27 2009-11-26 Peter Andrew Ferchmin Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
KR20090030347A (ko) 2006-07-19 2009-03-24 아스트라제네카 아베 신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도
US8003663B2 (en) 2006-08-01 2011-08-23 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
KR101378067B1 (ko) * 2006-08-10 2014-04-10 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 （ｒ,ｒ）―페노테롤 및 （ｒ,ｒ）―또는 （ｒ,ｓ）―페노테롤 유사체의 제조방법 및 이의 울혈성 심부전증 치료를 위한 용도
WO2008041914A1 (en) * 2006-10-06 2008-04-10 Astrazeneca Ab 5-(2-AMINO-L-HYDROXYETHYL)-8-HYDROXY-2-OXOQUINOLINE DERIVATIVES AND OTHER COMPOUNDS AS β2 -ADRENERGIC AGONISTS
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
BRPI0721039A2 (pt) 2006-12-19 2014-07-29 Astrazeneca Ab " derivados de quinuclidinol como antagonistas de receptores muscarínicos ".
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
DK2104535T3 (da) 2007-01-10 2011-04-04 Irm Llc Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
CA2677485A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
CN101687851B (zh) 2007-05-07 2013-02-27 诺瓦提斯公司 有机化合物
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
CN101910153B (zh) 2008-01-11 2014-01-22 诺华股份有限公司 作为激酶抑制剂的嘧啶类
EP2300464A1 (en) 2008-05-13 2011-03-30 AstraZeneca AB Quinuclidine derivatives as muscarinic m3 receptor antagonists
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
MX2010012492A (es) 2008-05-27 2010-12-21 Astrazeneca Ab Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4.
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
EA201001848A1 (ru) 2008-06-10 2011-08-30 Новартис Аг Производные пиразина в качестве блокаторов эпителиальных натриевых каналов
WO2009154557A1 (en) 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
SI2379507T1 (sl) 2008-12-30 2014-02-28 Pulmagen Therapeutics (Inflammation) Limited Spojine sulfonamida za zdravljenje respiratornih motenj
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012520686A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2756069A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1)gene expression using short interfering nucleic acid (sina)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411019A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
CA2759476C (en) 2009-04-30 2018-10-09 Julie Nicole Hamblin Novel compounds
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
PL2453894T3 (pl) 2009-07-15 2016-04-29 Theravance Biopharma R&D Ip Llc Postać krystaliczna wolnej zasady związku bifenylowego
JP2013508414A (ja) 2009-10-22 2013-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症および他の慢性疾患の治療のための組成物
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011084316A2 (en) 2009-12-16 2011-07-14 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
EP2544676B1 (en) 2010-03-10 2018-09-19 The United States of America, as represented by The Secretary, Department of Health and Human Services The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
ES2548036T3 (es) 2010-09-08 2015-10-13 Glaxosmithkline Intellectual Property Development Limited Polimorfos y sales de N-[5-[4-(5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-oxazol-2-il)-1H-indazol-6-il]-2-(metiloxi)-3-piridinil]metanosulfonamida
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
ES2532213T3 (es) 2010-10-21 2015-03-25 Glaxo Group Limited Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
JP2013544794A (ja) 2010-10-21 2013-12-19 グラクソ グループ リミテッド アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
SG192795A1 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as trk inhibitors
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
RS57075B1 (sr) 2013-03-15 2018-06-29 Verona Pharma Plc Kombinacija leka
AU2014336250A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
JP6475707B2 (ja) 2013-10-17 2019-02-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 呼吸器疾患の治療のためのｐｉ３ｋ阻害剤
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
WO2015162461A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
US20170100385A1 (en) 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
BR112021024668A2 (pt) 2019-06-10 2022-05-31 Novartis Ag Derivado de piridina e pirazina para o tratamento de fc, dpoc e bronquiectasia
KR20220052934A (ko) 2019-08-28 2022-04-28 노파르티스 아게 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
AT396333B (de) 1982-10-08 1993-08-25 Glaxo Group Ltd Vorrichtung zur verabreichung von medikamenten an patienten, einrichtung mit mehreren solchen vorrichtungen und traeger mit medikamentbehaeltern hiefuer
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4853381A (en) * 1984-04-17 1989-08-01 Glaxo Group Limited Ethanolamine compounds
DE3571808D1 (en) 1984-04-17 1989-08-31 Glaxo Group Ltd Ethanolamine compounds
FR2562889B1 (fr) * 1984-04-17 1988-10-28 Glaxo Group Ltd Composes de phenethanolamine. procede pour leur preparation et compositions pharmaceutiques les comprenant
GB8426200D0 (en) * 1984-10-17 1984-11-21 Glaxo Holdings Ltd Chemical compounds
IL75794A (en) 1984-07-13 1989-01-31 Glaxo Group Ltd 2-hydroxy-5-(1-hydroxy-2-(aralkyloxyalkylamino)ethyl)aniline derivatives,their preparation and pharmaceutical compositions containing them
DK163640C (da) 1985-07-30 1992-08-17 Glaxo Group Ltd Apparat til administrering af medikamenter
EP0223410A3 (en) 1985-10-16 1987-11-19 Glaxo Group Limited Ethanolamine derivatives
GB8525483D0 (en) 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
EP0220054A3 (en) 1985-10-16 1987-12-02 Glaxo Group Limited Ethanolamine derivatives
JPS6485964A (en) * 1987-03-12 1989-03-30 Glaxo Group Ltd Compound
GB8718940D0 (en) * 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
JPH0228141A (ja) * 1987-11-13 1990-01-30 Glaxo Group Ltd フェネタノールアミン誘導体
GB8909273D0 (en) * 1989-04-24 1989-06-07 Glaxo Group Ltd Chemical compounds
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
WO1993019749A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
GB9313574D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
WO1999016766A1 (en) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Benzodioxole derivatives
SI1070056T1 (en) 1998-03-14 2004-12-31 Altana Pharma Ag Phthalazinone pde iii/iv inhibitors
SI1212089T1 (sl) 1999-08-21 2006-08-31 Altana Pharma Ag Sinergisticna kombinacija roflumilasta in salmeterola

Similar Documents

Publication Publication Date Title
JP2004538259A5 (enExample)
JP4925074B2 (ja) ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
JP2005519083A5 (enExample)
JP2006504766A5 (enExample)
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
JP2007515468A5 (enExample)
JP2010018622A (ja) セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用
JP2004526720A5 (enExample)
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
AU2006332677A1 (en) Methods for treating cutaneous lupus using aminoisoindoline compounds
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
JP2019011343A (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
SG184721A1 (en) Method of treating polycystic kidney diseases with ceramide derivatives
JP2007514691A5 (enExample)
JP2003513075A5 (enExample)
WO2008005352A3 (en) Solid dose formulations of a thrombin receptor antagonist
JP2002534477A5 (enExample)
KR20050070024A (ko) 이소퀴놀린 화합물 및 그의 의약 용도
JP2007509052A5 (enExample)
KR20140121487A (ko) 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질
JP2701042B2 (ja) 抗鬱病剤作用を有する新規な結合生成物
AU739466B2 (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
EP2608782B1 (en) Novel use of leflunomide and malononitrilamides